您当前所在的位置:首页 > 产品中心 > 产品信息
Aminolevulinic acid_分子结构_CAS_106-60-5)
点击图片或这里关闭

Aminolevulinic acid

产品号 DB00855 公司名称 DrugBank
CAS号 106-60-5 公司网站 http://www.ualberta.ca/
分子式 C5H9NO3 电 话 (780) 492-3111
分子量 131.12986 传 真
纯 度 电子邮件 david.wishart@ualberta.ca
保 存 Chembase数据库ID: 733

产品价格信息

请登录

产品别名

标题
Aminolevulinic acid
IUPAC标准名
5-amino-4-oxopentanoic acid
IUPAC传统名
aminolevulinic acid
商标名
Aladerm
Levulan
Levulan Kerastick
Kerastick
别名
Aminolevulinate
ALA
delta-Aminolevulinic acid

产品登记号

PubChem CID 137
CAS号 106-60-5
PubChem SID 46506856

产品性质

疏水性(logP) -1.5
溶解度 Very soluble

产品详细信息

详细说明 (English)
Item Information
Drug Groups approved
Description A compound produced from succinyl-CoA and glycine as an intermediate in heme synthesis. It is used as a photochemotherapy for actinic keratosis. [PubChem]
Indication Aminolevulinic acid plus blue light illumination using a blue light photodynamic therapy illuminator is indicated for the treatment of minimally to moderately thick actinic keratoses of the face or scalp.
Pharmacology The metabolism of aminolevulinic acid (ALA) is the first step in the biochemical pathway resulting in heme synthesis. Aminolevulinic acid is not a photosensitizer, but rather a metabolic precursor of protoporphyrin IX (PpIX), which is a photosensitizer. The synthesis of ALA is normally tightly controlled by feedback inhibition of the enzyme, ALA synthetase, presumably by intracellular heme levels. ALA, when provided to the cell, bypasses this control point and results in the accumulation of PpIX, which is converted into heme by ferrochelatase through the addition of iron to the PpIX nucleus.
Toxicity Solution overdose have not been reported.
Affected Organisms
Humans and other mammals
Biotransformation Following topical administration, synthesis into protoporphyrin IX takes place in situ in the skin.
Absorption Oral bioavailability is 50-60%.
Half Life Mean half-life is 0.70 ± 0.18 h after the oral dose and 0.83 ± 0.05 h after the intravenous dose.
References
Stummer W, Pichlmeier U, Meinel T, Wiestler OD, Zanella F, Reulen HJ: Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol. 2006 May;7(5):392-401. [Pubmed]
Kennedy JC, Marcus SL, Pottier RH: Photodynamic therapy (PDT) and photodiagnosis (PD) using endogenous photosensitization induced by 5-aminolevulinic acid (ALA): mechanisms and clinical results. J Clin Laser Med Surg. 1996 Oct;14(5):289-304. [Pubmed]
External Links
Wikipedia
RxList
Drugs.com

参考文献

  • Stummer W, Pichlmeier U, Meinel T, Wiestler OD, Zanella F, Reulen HJ: Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol. 2006 May;7(5):392-401. Pubmed
  • Kennedy JC, Marcus SL, Pottier RH: Photodynamic therapy (PDT) and photodiagnosis (PD) using endogenous photosensitization induced by 5-aminolevulinic acid (ALA): mechanisms and clinical results. J Clin Laser Med Surg. 1996 Oct;14(5):289-304. Pubmed